Metabolic Research

Maridebart Cafraglutide (MariTide)

InvestigationalWeight & metabolic
Not yet scored

BioHarmony verdict

Awaiting review

No BioHarmony report yet. It is queued for review; until then, rely on the status and sources below.

Dosing as published

No approved-label or study protocol is recorded for Maridebart Cafraglutide (MariTide) yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

US approvalInvestigational
CompoundingNo FDA-approved product; compounding eligibility is not established
Last checked2026-09-02
Next review2026-10-02 (overdue, details paused)

Primary sources

Sources are still being reviewed for this compound.

  1. 6.5/10MOTS-cWorth tryingWeight & metabolicNot FDA approvedMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
  2. 6.2/10IpamorelinWorth tryingRecoveryNot FDA approvedIpamorelin is a selective growth-hormone secretagogue with strong receptor selectivity but almost no human efficacy data: its only completed human efficacy trial…
  3. 6.1/10TirzepatideWorth tryingWeight & metabolicFDA-approved product existsTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
  4. 6.0/10Semaglutide (GLP-1 Agonist)Worth tryingWeight & metabolicFDA-approved product existsSemaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 6.0-6.5/10 score holds…

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.